Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis
Whiting P, Al M, Burgers L, Westwood M, Ryder S, Hoogendoorn M, Armstrong N, Allen A, Severens H, Kleijnen J
Record ID 32013001082
English
Authors' objectives:
To review the clinical effectiveness and cost-effectiveness of ivacaftor for the treatment of CF in patients aged 6 years who have the G551D mutation.
Authors' recommendations:
The available evidence suggests that ivacaftor is a clinically effective treatment for patients with CF and the G551D mutation; the high cost of ivacaftor may prove an obstacle in the uptake of this treatment. The main priority for further research is the long-term effectiveness of ivacaftor.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.journalslibrary.nihr.ac.uk/hta/hta18180/#/abstract
URL for additional information:
http://www.journalslibrary.nihr.ac.uk/hta/volume-18/issue-18#hometab0
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Aminophenols
- Quinolones
- Cystic Fibrosis Transmembrane Conductance Regulator
- Cystic Fibrosis
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2014 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.